A 9th PML case with Tysabri since reintroduction – Biotechnology company Biogen Idec Inc. said late Friday a ninth Tysabri patient developed a potentially deadly brain infection since the drug was reintroduced to the market in 2006. The drug, which treats multiple sclerosis, was pulled from the market in 2005 following occurrences of a rare, but deadly, brain infection called progressive multifocal leukoencephalopathy. The drug was reintroduced in July of 2006, with restrictions and a monitoring program…more
Merck and Schering-Plough – more merger info, please (FTC).
Some interesting oncology/HIV links, with hat tip to Sally Church:
:: Glaxo drug delays kidney cancer progression – it will be interesting to see how it compares to, say, Sutent.
:: Perfusion treatment for liver cancer shows some promising results.
:: How does adrenal cancer form?
:: Combined retroviral and targeted chemotherapy treatment may flush out hide-and-seek virus remaining in immune cells.
PLUS – are too many patients self-diagnosing?
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply